Literature DB >> 22737271

Regulation of PI 3-K, PTEN, p53, and mTOR in Malignant and Benign Tumors Deficient in Tuberin.

Samy L Habib1, Anamika Yadav, Lenin Mahimainathan, Anthony J Valente.   

Abstract

The tuberous sclerosis complex (TSC) is caused by mutation in either of 2 tumor suppressor genes, TSC-1 (encodes hamartin) and TSC-2 (encodes tuberin). In humans, deficiency in TSC1/2 is associated with benign tumors in many organs, including renal angiomyolipoma (AML) but rarely renal cell carcinoma (RCC). In contrast, deficiency of TSC function in the Eker rat is associated with RCC. Here, we have investigated the activity of PI 3-K and the expression of PTEN, p53, tuberin, p-mTOR, and p-p70S6K in both Eker rat RCC and human renal AML. Compared to normal tissue, increased PI 3-K activity was detected in RCC of Eker rats but not in human AML tissue. In contrast, PTEN was highly expressed in AML but significantly reduced in the renal tumors of Eker rats. Phosphorylation on Ser(2448) of mTOR and Thr(389) of p70S6K were significantly increased in both RCC and AML compared to matching control tissue. Total tuberin was significantly decreased in AML while completely lost in RCC of Eker rats. Our data also show that while p53 protein expression is lost in rat RCC, it was highly elevated in AML. These novel data provide evidence that loss of TSC-2, PTEN, and p53 as well as activation of PI 3-K and mTOR is associated with kidney cancer in the Eker rat, while sustained expression of TSC-2, PTEN, and p53 may prevent progression of kidney cancer in TSC patients.

Entities:  

Keywords:  PTEN; RCC; angiomyolipoma; p53; tuberin

Year:  2011        PMID: 22737271      PMCID: PMC3379569          DOI: 10.1177/1947601912445376

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  34 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  The tuberous sclerosis complex.

Authors:  Peter B Crino; Katherine L Nathanson; Elizabeth Petri Henske
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

Review 3.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

Authors:  L C Cantley; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

4.  The coordinate regulation of the p53 and mTOR pathways in cells.

Authors:  Zhaohui Feng; Haiyan Zhang; Arnold J Levine; Shengkan Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

5.  Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions.

Authors:  E P Henske; B W Scheithauer; M P Short; R Wollmann; J Nahmias; N Hornigold; M van Slegtenhorst; C T Welsh; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

6.  Allele-specific tumor spectrum in pten knockin mice.

Authors:  Hui Wang; Matt Karikomi; Shan Naidu; Ravi Rajmohan; Enrico Caserta; Hui-Zi Chen; Maysoon Rawahneh; Julie Moffitt; Julie A Stephens; Soledad A Fernandez; Michael Weinstein; Danxin Wang; Wolfgang Sadee; Krista La Perle; Paul Stromberg; Thomas J Rosol; Charis Eng; Michael C Ostrowski; Gustavo Leone
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

7.  Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex.

Authors:  T Al-Saleem; L L Wessner; B W Scheithauer; K Patterson; E S Roach; S J Dreyer; K Fujikawa; J Bjornsson; J Bernstein; E P Henske
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

8.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

9.  Carcinomalike monotypic epithelioid angiomyolipoma in patients without evidence of tuberous sclerosis: a clinicopathologic and genetic study.

Authors:  G Martignoni; M Pea; F Bonetti; G Zamboni; C Carbonara; L Longa; C Zancanaro; M Maran; M Brisigotti; G M Mariuzzi
Journal:  Am J Surg Pathol       Date:  1998-06       Impact factor: 6.394

10.  Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.

Authors:  Sanjukta Chakraborty; S M Azeem Mohiyuddin; K S Gopinath; Arun Kumar
Journal:  BMC Cancer       Date:  2008-06-06       Impact factor: 4.430

View more
  13 in total

1.  The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch-Nodal Axis.

Authors:  Jun-Hung Cho; Bhaumik Patel; Santosh Bonala; Hossein Mansouri; Sasikanth Manne; Surya Kumari Vadrevu; Shanawaz Ghouse; Che-Pei Kung; Maureen E Murphy; Aristotelis Astrinidis; Elizabeth P Henske; David J Kwiatkowski; Maciej M Markiewski; Magdalena Karbowniczek
Journal:  Mol Cancer Res       Date:  2019-05-14       Impact factor: 5.852

2.  mTORC1 and p53: clash of the gods?

Authors:  Paul Hasty; Zelton Dave Sharp; Tyler J Curiel; Judith Campisi
Journal:  Cell Cycle       Date:  2013-01-01       Impact factor: 4.534

3.  A case of renal angiomyolipoma with intracardiac extension and asymptomatic pulmonary embolism.

Authors:  Xiaoman Li; Qingchang Li; Yuan Miao; Hongtao Xu; Yang Liu; Xueshan Qiu; En-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

4.  Boiling Histotripsy Ablation of Renal Cell Carcinoma in the Eker Rat Promotes a Systemic Inflammatory Response.

Authors:  George R Schade; Yak-Nam Wang; Samantha D'Andrea; Joo Ha Hwang; W Conrad Liles; Tatiana D Khokhlova
Journal:  Ultrasound Med Biol       Date:  2018-10-16       Impact factor: 2.998

5.  Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming.

Authors:  Laura C Armstrong; Grant Westlake; John P Snow; Bryan Cawthon; Eric Armour; Aaron B Bowman; Kevin C Ess
Journal:  Hum Mol Genet       Date:  2017-12-01       Impact factor: 6.150

6.  Activated p53 in the anti-apoptotic milieu of tuberous sclerosis gene mutation induced diseases leads to cell death if thioredoxin reductase is inhibited.

Authors:  ElHusseiny M M Abdelwahab; Judit Bovari-Biri; Gabor Smuk; Janos Fillinger; Donald McPhail; Vera P Krymskaya; Judit E Pongracz
Journal:  Apoptosis       Date:  2021-04-16       Impact factor: 4.677

7.  miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.

Authors:  Zhihong Zhuo; Huimin Yu
Journal:  Oncotarget       Date:  2017-04-25

8.  Identification of the miRNA-target gene regulatory network in intracranial aneurysm based on microarray expression data.

Authors:  Kezhen Wang; Xinmin Wang; Hongzhu Lv; Chengzhi Cui; Jiyong Leng; Kai Xu; Guosong Yu; Jianwei Chen; Peiyu Cong
Journal:  Exp Ther Med       Date:  2017-04-25       Impact factor: 2.447

9.  mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

Authors:  Daisuke Ishikawa; Shinji Takeuchi; Takayuki Nakagawa; Takako Sano; Junya Nakade; Shigeki Nanjo; Tadaaki Yamada; Hiromichi Ebi; Lu Zhao; Kazuo Yasumoto; Takahiro Nakamura; Kunio Matsumoto; Hiroshi Kagamu; Hirohisa Yoshizawa; Seiji Yano
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

10.  Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.

Authors:  Seok-Hyung Kim; Marie L Kowalski; Robert P Carson; L Richard Bridges; Kevin C Ess
Journal:  Dis Model Mech       Date:  2013-03-27       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.